Phase 1/2 showed preliminary results from a clinical trial showing that it was well tolerated and that even a single dose appeared to produce a strong immune response in about 800 participants. The trial included two age groups: 18- to 55-year-olds and 65- and older, and looked at the safety …
Read More »